Medikra, a Malaysia-based developer of plant-based bioactives focused on obesity and metabolic syndrome, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering.
The Petaling Jaya, Malaysia-based company plans to raise $20 million by offering 3.6 million shares at a price range of $5 to $6. At the midpoint of the proposed range, Medikra would command a market cap of $161 million.
Medikra is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical-grade botanical therapeutics. The company advances plant-derived bioactive ingredients into regulated medicines by integrating proprietary botanical extraction, analytical standardization, preclinical and clinical development, and multi-omics (e.g. proteomics and transcriptomics) analysis. Medikra's lead product candidate, SKF7, is a patented standardized extract of Labisia pumila, a medicinal plant indigenous to Malaysia, under development for the treatment of abdominal obesity and metabolic syndrome. SKF7 has been evaluated in multicenter, randomized, placebo-controlled Phase I and Phase II clinical trials conducted in Malaysia, Indonesia, and India.
The Petaling Jaya, Malaysia-based company was founded in 2006 and plans to list on the NYSE American under the symbol MDKR. Medikra filed confidentially on August 22, 2025. Brookline Capital Markets is the sole bookrunner on the deal.
